My Watchlist Items

      No Watchlist
Prometheus Biosciences, Inc. (RXDX)
   35.29   5.1600018(+17.125793%)
TitleNamePayCurrency PayGenderYear BornTitle Since
Chief Medical Officer Dr. Allison Luo M.D. 586130 USD 1973 N/A
Chief Financial Officer & Treasurer Dr. Keith W. Marshall M.B.A., MBA, Ph.D. 458220 USD 1968 N/A
Pres, Chief Executive Officer & Chairman Mr. Mark C. McKenna 1510000 USD male 1980 N/A
SymbolDateRatingRating Score Rating Details
RXDX 14 January, 2022 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 13 January, 2022 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 12 January, 2022 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 11 January, 2022 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 10 January, 2022 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 7 January, 2022 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 6 January, 2022 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 5 January, 2022 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 4 January, 2022 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 3 January, 2022 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 31 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 30 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 29 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 28 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 27 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 23 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 22 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 21 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 20 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 17 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 16 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 15 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 14 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 13 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 10 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 9 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 8 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 7 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 6 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 3 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 2 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 1 December, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 30 November, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 29 November, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 26 November, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 24 November, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 23 November, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 22 November, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 19 November, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 18 November, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 17 November, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 16 November, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 15 November, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 12 November, 2021 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 11 November, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 10 November, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 9 November, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 8 November, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 5 November, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 4 November, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 3 November, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 2 November, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 1 November, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 29 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 28 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 27 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 26 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 25 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 22 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 21 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 20 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 19 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 18 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 15 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 14 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 13 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 12 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 11 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 8 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 7 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 6 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 5 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 4 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 1 October, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 30 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 29 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 28 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 27 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 24 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 23 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 22 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 21 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 20 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 17 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 16 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 15 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 14 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 13 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 10 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 9 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 8 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 7 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 3 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 2 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 1 September, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 31 August, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 30 August, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 27 August, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 26 August, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
RXDX 25 August, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
HolderSharesDate ReportedChange
72 INVESTMENT HOLDINGS, LLC 1848024 30 September, 2021 0
ADAGE CAPITAL PARTNERS GP LLC 347315 30 September, 2021 -27685
AMERITAS INVESTMENT PARTNERS, INC. 886 30 September, 2021 0
AMERICAN INTERNATIONAL GROUP INC 6186 30 September, 2021 -147
BANK OF NEW YORK MELLON CORP 33854 30 September, 2021 2450
BANK OF AMERICA CORP /DE/ 5707 30 September, 2021 1566
BLACKROCK INC. 940120 30 September, 2021 942
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 6073 30 September, 2021 -9541
CHI ADVISORS LLC 2862059 30 September, 2021 10050
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 75711 30 September, 2021 583
CITIGROUP INC 1290 30 September, 2021 753
CITADEL ADVISORS LLC 0 30 September, 2021 -38438
CORMORANT ASSET MANAGEMENT, LLC 1848024 30 September, 2021 0
DEUTSCHE BANK AG\ 6500 30 September, 2021 -209
ERGOTELES LLC 8791 30 September, 2021 8791
EVENTIDE ASSET MANAGEMENT, LLC 3714032 30 September, 2021 0
FMR LLC 301200 30 September, 2021 -111600
FRANKLIN RESOURCES INC 557100 30 September, 2021 0
GEODE CAPITAL MANAGEMENT, LLC 215174 30 September, 2021 4562
GOLDMAN SACHS GROUP INC 169734 30 September, 2021 169734
HHLR ADVISORS, LTD. 200000 30 September, 2021 0
JUMP FINANCIAL, LLC 0 30 September, 2021 -10311
KINGDON CAPITAL MANAGEMENT, L.L.C. 0 30 September, 2021 -8317
JPMORGAN CHASE & CO 4329 30 September, 2021 -2493
LAURION CAPITAL MANAGEMENT LP 168798 30 September, 2021 106714
LEGAL & GENERAL GROUP PLC 951 30 September, 2021 49
LMR PARTNERS LLP 50000 30 September, 2021 -45045
METLIFE INVESTMENT ADVISORS, LLC 4911 30 September, 2021 4911
METROPOLITAN LIFE INSURANCE CO/NY 3715 30 September, 2021 3715
MORGAN STANLEY 2385 30 September, 2021 -468
NEW YORK STATE COMMON RETIREMENT FUND 9817 30 September, 2021 117
OCTAGON CAPITAL ADVISORS LP 200000 30 September, 2021 0
NUVEEN ASSET MANAGEMENT, LLC 39931 30 September, 2021 7558
NORTHERN TRUST CORP 101026 30 September, 2021 -9712
ORBIMED ADVISORS LLC 250000 30 September, 2021 0
PANAGORA ASSET MANAGEMENT INC 0 30 September, 2021 -245
PERCEPTIVE ADVISORS LLC 3314032 30 September, 2021 0
PLATINUM INVESTMENT MANAGEMENT LTD 502520 30 September, 2021 147619
POINT72 ASSET MANAGEMENT, L.P. 736402 30 September, 2021 -27700
ROCK SPRINGS CAPITAL MANAGEMENT LP 610136 30 September, 2021 14040
RHUMBLINE ADVISERS 10894 30 September, 2021 525
RTW INVESTMENTS, LLC 3264031 30 September, 2021 0
ROYAL BANK OF CANADA 1677 30 September, 2021 904
SG AMERICAS SECURITIES, LLC 6396 30 September, 2021 6396
STATE OF WISCONSIN INVESTMENT BOARD 14700 30 September, 2021 0
STATE STREET CORP 197266 30 September, 2021 41465
STRS OHIO 2600 30 September, 2021 0
SUVRETTA CAPITAL MANAGEMENT, LLC 480480 30 September, 2021 -145145
TOWER RESEARCH CAPITAL LLC 406 30 September, 2021 -593
UBS GROUP AG 873 30 September, 2021 873
VIRTUS ETF ADVISERS LLC 9043 30 September, 2021 -476
VANGUARD GROUP INC 542909 30 September, 2021 3548
WOODLINE PARTNERS LP 207537 30 September, 2021 4855
WELLS FARGO & COMPANY/MN 15446 30 September, 2021 15373
SymbolTransaction DateReporting CikSecurities Owned Company CikReporting NameAcquistion Or DispositionForm Type Securities TransactedSecurity NameLink
RXDX 1 December, 2021 0001749623 122531 0001718852 McKenna Mark C. D 4 15400 Stock Option (Right to Buy) View
RXDX 1 December, 2021 0001749623 15400 0001718852 McKenna Mark C. A 4 15400 Common Stock View
RXDX 14 November, 2021 0001488486 1083 0001718852 Adams Helen C. A 4 1083 Stock Option (Right to Buy) View
RXDX 14 November, 2021 0001110744 541 0001718852 Hassan Fred A 4 541 Stock Option (Right to Buy) View
RXDX 14 November, 2021 0001242215 2165 0001718852 PAPA JOSEPH C A 4 2165 Stock Option (Right to Buy) View
RXDX 14 November, 2021 0001734751 70371 0001718852 Stenhouse Mark A 4 70371 Stock Option (Right to Buy) View
RXDX 14 November, 2021 0001711464 54132 0001718852 Andrews Timothy K. A 4 54132 Stock Option (Right to Buy) View
RXDX 14 November, 2021 0001714828 102155 0001718852 Marshall Keith W A 4 102155 Stock Option (Right to Buy) View
RXDX 14 November, 2021 0001849225 113677 0001718852 Luo Allison A 4 113677 Stock Option (Right to Buy) View
RXDX 14 November, 2021 0001749623 290000 0001718852 McKenna Mark C. A 4 290000 Stock Option (Right to Buy) View
RXDX 8 September, 2021 0001849225 4500 0001718852 Luo Allison A 4 4500 Stock Option (Right to Buy) View
RXDX 14 May, 2021 0001110744 40000 0001718852 Hassan Fred A 4 40000 Stock Option (Right to Buy) View
RXDX 14 April, 2021 0001850353 40000 0001718852 Hendrix Martin A 4 40000 Stock Option (Right to Buy) View
RXDX 14 April, 2021 0001850350 40000 0001718852 Laur James A 4 40000 Stock Option (Right to Buy) View
RXDX 16 March, 2021 0001224962 0 0001718852 PERCEPTIVE ADVISORS LLC D 4 14462623 Series D-2 Convertible Preferred Stock View
RXDX 16 March, 2021 0001224962 0 0001718852 PERCEPTIVE ADVISORS LLC D 4 14462623 Series D-2 Convertible Preferred Stock View
RXDX 16 March, 2021 0001224962 3314032 0001718852 PERCEPTIVE ADVISORS LLC A 4 850000 Common Stock View
RXDX 16 March, 2021 0001850122 0 0001718852 Point72 Biotech Private Investments, LLC D 4 10846968 Series D-2 Preferred Stock View
RXDX 16 March, 2021 0001850122 2648024 0001718852 Point72 Biotech Private Investments, LLC A 4 800000 Common Stock View
RXDX 16 March, 2021 0001850122 763327 0001718852 Point72 Biotech Private Investments, LLC A 4 763327 Common Stock View
RXDX 16 March, 2021 0001583977 0 0001718852 Cormorant Asset Management, LP D 4 1084696 Series D-2 Convertible Preferred Stock View
RXDX 16 March, 2021 0001583977 2223022 0001718852 Cormorant Asset Management, LP A 4 375000 Common Stock View
RXDX 16 March, 2021 0001583977 1848022 0001718852 Cormorant Asset Management, LP A 4 1848022 Common Stock View
RXDX 16 March, 2021 0001488486 500 0001718852 Adams Helen C. A 4 500 Common Stock View
RXDX 16 March, 2021 0001242215 15000 0001718852 PAPA JOSEPH C A 4 15000 Common Stock View
RXDX 16 March, 2021 0001734751 14000 0001718852 Stenhouse Mark A 4 14000 Common Stock View
RXDX 16 March, 2021 0001493215 800000 0001718852 RTW INVESTMENTS, LP A 4 800000 Series D-1 Preferred Stock View
RXDX 16 March, 2021 0001493215 0 0001718852 RTW INVESTMENTS, LP D 4 10177703 Series D-1 Preferred Stock View
RXDX 16 March, 2021 0001493215 3264031 0001718852 RTW INVESTMENTS, LP A 4 1446262 Common Stock View
RXDX 16 March, 2021 0001493215 1817769 0001718852 RTW INVESTMENTS, LP A 4 1017769 Common Stock View
RXDX 16 March, 2021 0001493215 1817769 0001718852 RTW INVESTMENTS, LP A 4 1017769 Series D-1 Preferred Stock View
RXDX 16 March, 2021 0001493215 3264031 0001718852 RTW INVESTMENTS, LP A 4 1446262 Common Stock View
RXDX 16 March, 2021 0001583977 0 0001718852 Cormorant Asset Management, LP D 4 1084696 Series D-2 Convertible Preferred Stock View
RXDX 16 March, 2021 0001583977 1848022 0001718852 Cormorant Asset Management, LP A 4 1848022 Common Stock View
RXDX 16 March, 2021 0001583977 2223022 0001718852 Cormorant Asset Management, LP A 4 375000 Common Stock View
RXDX 16 March, 2021 0001583977 1848022 0001718852 Cormorant Asset Management, LP A 4 1848022 Common Stock View
RXDX 16 March, 2021 0001583977 2223022 0001718852 Cormorant Asset Management, LP A 4 375000 Common Stock View
RXDX 16 March, 2021 0001269910 4646942 0001718852 CEDARS SINAI MEDICAL CENTER A 4 254442 Common Stock View
RXDX 16 March, 2021 0001269910 4392500 0001718852 CEDARS SINAI MEDICAL CENTER A 4 2500000 Common Stock View
RXDX 16 March, 2021 0001269910 692500 0001718852 CEDARS SINAI MEDICAL CENTER A 4 100000 Series A Preferred Stock View
RXDX 16 March, 2021 0001269910 5008508 0001718852 CEDARS SINAI MEDICAL CENTER A 4 361566 Common Stock View
RXDX 16 March, 2021 0001269910 1892500 0001718852 CEDARS SINAI MEDICAL CENTER A 4 1200000 Common Stock View
RXDX 16 March, 2021 0001402530 13333 0001718852 Yamada Tadataka A 4 13333 Common Stock View
RXDX 16 March, 2021 0001402530 0 0001718852 Yamada Tadataka D 4 133334 Series B Preferred Stock View
RXDX 16 March, 2021 0001269910 0 0001718852 CEDARS SINAI MEDICAL CENTER D 4 1000000 Series A Preferred Stock View
RXDX 16 March, 2021 0001850122 1848024 0001718852 Point72 Biotech Private Investments, LLC A 4 1084697 Common Stock View
RXDX 16 March, 2021 0001850122 763327 0001718852 Point72 Biotech Private Investments, LLC A 4 763327 Common Stock View
RXDX 16 March, 2021 0001850122 2648024 0001718852 Point72 Biotech Private Investments, LLC A 4 800000 Common Stock View
RXDX 16 March, 2021 0001850122 1848024 0001718852 Point72 Biotech Private Investments, LLC A 4 1084697 Common Stock View
RXDX 16 March, 2021 0001850122 2648024 0001718852 Point72 Biotech Private Investments, LLC A 4 800000 Common Stock View
RXDX 16 March, 2021 0001850122 763327 0001718852 Point72 Biotech Private Investments, LLC A 4 763327 Common Stock View
RXDX 16 March, 2021 0001850122 0 0001718852 Point72 Biotech Private Investments, LLC D 4 10846968 Series D-2 Preferred Stock View
RXDX 16 March, 2021 0001493215 800000 0001718852 RTW INVESTMENTS, LP A 4 800000 Common Stock View
RXDX 16 March, 2021 0001224962 1017770 0001718852 PERCEPTIVE ADVISORS LLC A 4 1017770 Common Stock View
RXDX 16 March, 2021 0001224962 2464032 0001718852 PERCEPTIVE ADVISORS LLC A 4 1446262 Common Stock View
RXDX 11 March, 2021 0001410289 40000 0001718852 Szela Mary T A 4 40000 Stock Option (Right to Buy) View
RXDX 8 February, 2018 0001652037 0 0001557421 Start Valerie Denise Harding D 4 29188 Common Stock View
RXDX 8 February, 2018 0001414894 0 0001557421 Kuhlen Christian V D 4 22019 Common Stock View
RXDX 8 February, 2018 0001602227 0 0001557421 Hornby Zachary D 4 165748 Common Stock View
RXDX 8 February, 2018 0001660105 0 0001557421 McCarthy William R D 4 22199 Common Stock View
RXDX 8 February, 2018 0001283290 0 0001557421 Lim Jonathan E D 4 179661 Common Stock View
RXDX 8 February, 2018 0001379372 0 0001557421 Dreismann Heiner D 4 6666 Stock Option (Right to Buy) View
RXDX 8 February, 2018 0001455228 0 0001557421 Casdin Alexander W. D 4 706464 Common Stock View
RXDX 8 February, 2018 0001608936 0 0001557421 Chacko Jacob D 4 70572 Common Stock View
RXDX 8 February, 2018 0001533451 0 0001557421 Hoerter Steven L. D 4 24000 Stock Option (Right to Buy) View
RXDX 8 February, 2018 0001601960 0 0001557421 Bristol James A D 4 21845 Common Stock View
RXDX 8 February, 2018 0001586894 0 0001557421 Multani Pratik S D 4 74134 Common Stock View
RXDX 8 February, 2018 0001368924 0 0001557421 Freddo James L D 4 3000 Common Stock View
RXDX 5 January, 2018 0001608936 70572 0001557421 Chacko Jacob A 4 4400 Common Stock View
RXDX 5 January, 2018 0001586894 74134 0001557421 Multani Pratik S A 4 4400 Common Stock View
RXDX 26 December, 2017 0001283290 179661 0001557421 Lim Jonathan E D 4 19006 Common Stock View
RXDX 26 December, 2017 0001652037 29188 0001557421 Start Valerie Denise Harding D 4 2066 Common Stock View
RXDX 26 December, 2017 0001414894 22019 0001557421 Kuhlen Christian V D 4 1315 Common Stock View
RXDX 26 December, 2017 0001602227 165748 0001557421 Hornby Zachary D 4 18552 Common Stock View
RXDX 26 December, 2017 0001660105 22199 0001557421 McCarthy William R D 4 1135 Common Stock View
RXDX 22 December, 2017 0001283290 198667 0001557421 Lim Jonathan E A 4/A 68334 Common Stock View
RXDX 22 December, 2017 0001652037 31254 0001557421 Start Valerie Denise Harding A 4 23334 Common Stock View
RXDX 22 December, 2017 0001602227 184300 0001557421 Hornby Zachary A 4 37167 Common Stock View
RXDX 22 December, 2017 0001414894 23334 0001557421 Kuhlen Christian V A 4 23334 Common Stock View
RXDX 22 December, 2017 0001660105 23334 0001557421 McCarthy William R A 4 23334 Common Stock View
RXDX 22 December, 2017 0001586894 69734 0001557421 Multani Pratik S A 4 23334 Common Stock View
RXDX 22 December, 2017 0001608936 66172 0001557421 Chacko Jacob A 4 23334 Common Stock View
RXDX 13 June, 2017 0001601960 20000 0001557421 Bristol James A A 4 20000 Stock Option (Right to Buy) View
RXDX 13 June, 2017 0001533451 11666 0001557421 Hoerter Steven L. A 4 11666 Stock Option (Right to Buy) View
RXDX 13 June, 2017 0001455228 20000 0001557421 Casdin Alexander W. A 4 20000 Stock Option (Right to Buy) View
RXDX 13 June, 2017 0001379372 20000 0001557421 Dreismann Heiner A 4 20000 Stock Option (Right to Buy) View
RXDX 13 June, 2017 0001368924 20000 0001557421 Freddo James L A 4 20000 Stock Option (Right to Buy) View
RXDX 3 May, 2017 0001602227 135744 0001557421 Hornby Zachary A 4 2083 Common Stock View
RXDX 3 May, 2017 0001602227 137133 0001557421 Hornby Zachary A 4 1389 Common Stock View
RXDX 3 May, 2017 0001602227 147133 0001557421 Hornby Zachary A 4 10000 Common Stock View
RXDX 3 May, 2017 0001602227 0 0001557421 Hornby Zachary D 4 2083 Stock Option (Right to Buy) View
RXDX 3 May, 2017 0001602227 40000 0001557421 Hornby Zachary D 4 10000 Stock Option (Right to Buy) View
RXDX 13 February, 2017 0001283290 130333 0001557421 Lim Jonathan E A 4 6945 Common Stock View
RXDX 13 February, 2017 0001283290 0 0001557421 Lim Jonathan E D 4 6945 Stock Option (Right to Buy) View
RXDX 5 January, 2017 0001283290 120000 0001557421 Lim Jonathan E A 4 120000 Stock Option (Right to Buy) View
RXDX 5 January, 2017 0001608936 50000 0001557421 Chacko Jacob A 4 50000 Stock Option (Right to Buy) View
RXDX 5 January, 2017 0001652037 50000 0001557421 Start Valerie Denise Harding A 4 50000 Stock Option (Right to Buy) View
RXDX 5 January, 2017 0001414894 25000 0001557421 Kuhlen Christian V A 4 25000 Stock Option (Right to Buy) View
RXDX 5 January, 2017 0001602227 60000 0001557421 Hornby Zachary A 4 60000 Stock Option (Right to Buy) View
RXDX 5 January, 2017 0001601960 21845 0001557421 Bristol James A A 4 178 Common Stock View
SymbolDatePeriodDownload XLSX File
RXDX 2021 Q3 Download XLSX File
RXDX 2021 Q1 Download XLSX File
RXDX 2021 Q2 Download XLSX File

Charts

Company Historical Earnings

DateSymbolEPSEPS EstimatedTimeRevenueRevenue Estimated
12 November, 2021 RXDX -0.7 -0.7 bmo 1006000 876193
11 August, 2021 RXDX -0.49 -0.49 bmo 326000 326000
13 May, 2021 RXDX -1.67 -1.67 bmo 760000 1719243
12 March, 2021 RXDX bmo 0 0

Company Profile

Company Name Prometheus Biosciences, Inc.
Symbol RXDX
Currency USD
Price 35.29
Exchange Name Nasdaq Global Select (NASDAQ)
Industry Biotechnology
CEO Mr. Mark C. McKenna
Sector Healthcare
Country US
Full Time Employees 24
Phone 858 824 0895
Address 9410 Carroll Park Drive
City San Diego
State CA
Zip 92121
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 2016 and is based in San Diego, California.
>

FREE

Get the most important breaking news and analyses for Free.

Thank you for subscribing.

Something went wrong.